title: Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3.
abstract: A new class of pyrimidine-based Janus tyrosine kinase 3 (JAK3) inhibitors are described. Many of these inhibitors showed low nanomolar activity against JAK3.
authors.affiliation: Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Rd., Mason, OH 45040, USA. jack.01.chen@gmail.com
authors.forename: Jack J
authors.initials: JJ
authors.lastname: Chen
authors.forename: Kumar D
authors.initials: KD
authors.lastname: Thakur
authors.forename: Michael P
authors.initials: MP
authors.lastname: Clark
authors.forename: Steven K
authors.initials: SK
authors.lastname: Laughlin
authors.forename: Kelly M
authors.initials: KM
authors.lastname: George
authors.forename: Roger G
authors.initials: RG
authors.lastname: Bookland
authors.forename: Jan R
authors.initials: JR
authors.lastname: Davis
authors.forename: Edward J
authors.initials: EJ
authors.lastname: Cabrera
authors.forename: Vijay
authors.initials: V
authors.lastname: Easwaran
authors.forename: Biswanath
authors.initials: B
authors.lastname: De
authors.forename: Y
authors.initials: Y
authors.lastname: George Zhang
mesh_terms: D053616:Janus Kinase 3 / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000737:chemistry* / Q000494:pharmacology*
chemical_list: D011743:Pyrimidines; D053616:Janus Kinase 3